Rebecca Blanchard

Rebecca Blanchard is an accomplished leader in clinical pharmacology with extensive experience in drug development and pharmacogenetics. Currently serving as Vice President of Clinical Pharmacology at Oruka Therapeutics since October 2024, Rebecca oversees the clinical pharmacology aspects of drug development, including regulatory strategy and clinical pharmacokinetics. Previously, as President of Rebecca Blanchard Consulting LLC from June 2022 to July 2025, consultation services focused on clinical pharmacology and drug development. Rebecca also held key roles at CRISPR Therapeutics and Merck, specializing in cancer immunotherapy. With a strong academic background, including a Ph.D. in Pharmaceutical Chemistry from the University of Utah and post-doctoral training in pharmacogenetics at the Mayo Clinic Alix School of Medicine, Rebecca Blanchard is recognized for expertise in translating preclinical data into clinical applications.